The Pacassa SW discovery is a major milestone for the Block 3/05 partnership, representing the first well delivered on Block 3/05 in more than a decade,
— Paul Mcdade, Chief Executive
”
Afentra (AIM:AET), the AIM-listed upstream oil and gas company, shares surged 10.7% to 70.3p after the AIM-listed firm struck oil at its Pacassa SW well in Angola.
This transaction validates our strategy of converting platform science into non-dilutive commercial cash flows,
— Che Connon, Chief Executive, BSF Enterprise.
”
BSF Enterprise (LSE:BSFA), the biotechnology company developing tissue engineering and bioactive materials, has agreed Heads of Terms granting SCHAKAU Managementberatung exclusive worldwide rights to commercialise its ETSYL peptide (palmitoyl pentapeptide-87) in cosmetics, skincare and luxury…
We believe domestic cement producers should be allowed to compete fairly with overseas manufacturers, who do not face the same high energy prices and carbon taxes
— Rob Wood, Chief Executive, Breedon GB
”
Breedon Group (LSE:BREE), a vertically-integrated construction materials group operating in Great Britain, Ireland and the United States, gave an update on its Back British Cement campaign, launched in January to push for action to secure domestic cement production.
The direction of travel is unmistakable, every new authorisation potentially widens our customer funnel.
— Jason Drummond, Chief Executive
”
MedPal AI (AIM:MPAL), the AI-native digital health and pharmacy group, said the UK's medicines regulator has authorised orforglipron, Eli Lilly's once daily oral GLP-1 tablet sold under the brand Foundayo.
After years of impasse, our exploration rights are now secure and the Company is free to resume exploration of this exciting project
— Patrick Cheetham, Executive Chairman
”
Sunrise Resources (AIM:SRES), the AIM-listed gold and industrial minerals explorer, said the Government of Western Australia has granted Prospecting Licence 51/3378 over the high-grade gold target at its Bakers Gold Project.
It gives us a clear framework to advance responsibly in Madagascar and, critically, clears the path to our Proof of Concept pilot plant and onsite laboratory.
— Harena, Executive Chairman
”
Harena Rare Earths (LSE:HREE) has signed the Cahier des Charges Minières (CCM), or Mining Terms and Conditions, with Madagascar's Ministry of Mines.
FY2026 was a pivotal year for Seeing Machines, with record Automotive production volumes, strong revenue growth and a profitable second half that demonstrates the operating leverage in our business,
— Paul Mcglone, Chief Executive
”
Seeing Machines (AIM:SEE) shares shot up around 9% on Tuesday, to 5.17p, after the AIM-listed maker of AI-powered driver monitoring technology announced financials ahead of market expectations, with adjusted revenue up 45% to $76.3m in the year ended 30 June, from $52.8m in FY2025.
Bellway has delivered a robust performance and growth in volume output, despite ongoing headwinds for our industry
— Jason Honeyman, Chief Executive
”
Bellway (LSE:BWY) told investors it grew total housing completions by 10.8% to 9,695 homes in the year to 31 July, beating its previously guided range of 9,300 to 9,500 homes.
The quickest way to build further resource tonnes at Santa Helena is by drilling thick layers of mineralisation,
— Gilbert Clark, CEO
”
Meridian Mining (LSE:MNO), the London-listed explorer developing the Cabaçal gold-copper-silver project in Mato Grosso, Brazil, has drilled multiple stacked layers of gold-copper-silver and zinc-lead mineralisation below its Santa Helena resource area.
That is exactly the sort of position we want to test for sulphide accumulation,
— Richard Montjoie
”
URU Metals (LSE:URU) said 3D geological modelling at its Zeb Nickel Project in Limpopo, South Africa has established a close spatial link between known nickel-copper-platinum group elements (Ni-Cu-PGE) mineralisation and its strongest electromagnetic (EM) survey responses.
Corporate finance dominated health and biotech news, with a clinical-stage CNS specialist tapping fresh institutional capital, a pharma major refinancing in the bond markets, a boardroom transition at a fibrosis-focused drug repurposer, and a small debt conversion at a tissue-engineering group.
